Objectives: The aim of the study was to compare the intraindividual plasma and intracellular peripheral blood mononuclear cell (PBMC) pharmacokinetics of tenofovir (TFV) and its intracellular metabolite, TFV-diphosphate (TFV-DP) in patients switched from a fixed-dose combination (FDC) tablet of TFV disoproxil fumarate (TDF)/emtricitabine (FTC)/elvitegravir (EVG)/cobicistat (COBI) to a FDC containing TFV alafenamide (TAF)/FTC/EVG/COBI. Methods: Single, sparse plasma and PBMC samples were collected during TDF therapy and 4-8 weeks post-switch to the TAF-containing regimen. Plasma TFV and cell associated TFV-DP concentrations were determined with validated liquid chromatography tandem mass spectrometry methods. PBMC cell enumeration was performed by quantification of RNaseP (RPP30) gene copy numbers using a highly sensitive droplet digital PCR assay. Plasma and PBMC pharmacokinetics were summarized as geometric mean and compared as a geometric mean ratio with a Wilcoxon signed-rank test.
Introduction
Tenofovir (TFV) alafenamide (TAF) is a novel prodrug of the antiretroviral agent TFV. Recently, TAF has been included as a first-line recommended nucleotide reverse transcriptase inhibitor in the treatment of antiretroviral therapy (ART)-naïve and ART-experienced patients by both the United States Department of Health and Human Services as well as the European AIDS Clinical Society and International Antiviral Society treatment guidelines [1] [2] [3] . Two randomized phase 3 studies of TAF compared with an older TFV prodrug, TFV disoproxil fumarate (TDF), during initial treatment of HIV infection demonstrated noninferiority of TAF [4, 5] . A third phase 3 trial in virologically suppressed individuals receiving TDF-containing ART, randomized to either a TAF substitution or continuation of TDF, showed no difference in maintenance of virologic suppression [6] .
Initial clinical studies suggest TAF possesses a superior safety profile related to renal and bone adverse events when compared with TDF [5, 7] . The improved safety profile of TAF is thought to be due to substantially lower plasma TFV exposure resulting from a lower dose of TAF (either 10 or 25 mg) vs. the currently used dose of TDF (300 mg), as higher plasma TFV exposure has been shown to correlate with both renal and bone toxicity [8] . Parallel group pharmacokinetics from three studies demonstrate 90% lower plasma TFV exposure, whereas conversely attaining a roughly four-fold increase in the intracellular active metabolite of TFV, TFV-diphosphate (TFV-DP), in participants receiving TAF vs. TDF [9, 10] . The increased intracellular concentrations of TFV-DP achieved when administered as TAF may be related to the increased plasma stability of the TAF prodrug as compared with TDF, as the prodrugs of TFV more readily enter cells as compared with TFV itself [11] .
Taken collectively, these studies present a rationale for switching persons with HIV infection who are virologically suppressed on a TDF-containing regimen to a similar TAF-containing regimen, especially those at higher risk for renal impairment or bone mineral density loss. In 2015, the first TAF containing fixed-dose combination product was approved by the US Food and Drug Administration, and subsequently recommended as a first-line ARTregimen by HIV guidelines [1] [2] [3] . In this study, we investigated the intraindividual pharmacokinetics of plasma TFV and intracellular peripheral blood mononuclear cell (PBMC) TFV-DP concentrations in patients undergoing a planned switch from a TDF-containing regimen [TDF/emtricitabine (FTC)/elvitegravir (EVG)/cobicistat (COBI)] to a TAF-containing regimen (TAF/FTC/EVG/COBI).
Methods
A single-arm, prospective, nonrandomized, cross-over pharmacokinetic study was conducted at the University of Nebraska Medical Center (UNMC). Consecutive patients for whom a switch from TDF/FTC/EVG/ COBI to TAF/FTC/EVG/COBI was planned were approached during routine clinic visits and invited to participate. Entry criteria were age more than 19 years, diagnosis of HIV-infection, receiving TDF 300 mg/FTC 200 mg/EVG 150 mg/COBI 150 mg once daily for at least 4 weeks prior to enrollment, and switching to TAF 10 mg/FTC 200 mg/EVG 150 mg/COBI 150 mg once daily therapy. Exclusion criteria were HIV RNA more than 50 copies/ml after 6 months on ART, or after previously being virologically suppressed on ART. In addition, patients could not be receiving any concomitant medications that are contraindicated with TDF, FTC, EVG, COBI or TAF [12, 13] . Data on demographics, medical history, CD4
þ cell count and HIV-RNA at entry were abstracted from participant medical records.
Pharmacokinetic evaluations
Participants underwent pharmacokinetic sampling at two study visits: the first was during TDF/FTC/EVG/COBI therapy, and the second was 4-8 weeks after switching to TAF/FTC/EVG/COBI. The 4-8-week cross over period was based on TFVand TFV-DP half-lives as well as rates of enzyme and transporter synthesis and turnover which have been previously reported to normalize by 28 days postperturbation [14] [15] [16] . Participants were asked to come to clinic at the same time of day for each pharmacokinetic visit, although pharmacokinetic samples were collected irrespective of the time postdose. Participants were asked to provide the time of the three previous doses of ART taken prior to each pharmacokinetic study visit. If a participant had missed any of the three previous ART doses, their pharmacokinetic sampling visit was rescheduled to a later date in which adherence to study medication was ensured. At each of the visits, 5 ml of whole blood was collected by venipuncture into a Vacutainer spray dried K2 EDTA tube (Becton Dickinson, Franklin Lakes, New Jersey, USA) for plasma TFV concentration determination. Blood was immediately processed upon collection. Plasma was separated by centrifugation (1200 Â g for 10 min at 4 8C) and transferred to labeled polypropylene cryotubes. Plasma was stored at À80 8C until analysis. PBMC's were collected at each of the two pharmacokinetic study visits as previously described [17] . Briefly, 6-8 ml of blood was collected by venipuncture into cell preparation tubes (CPT) with sodium heparin anticoagulant. The CPT tubes were centrifuged and mononuclear cells collected. Cells were washed via a rapid spin through oil approach prior to placing the cells in 70% methanol for long-term storage at À80 8C. PBMC cell enumeration was performed by quantification of RNaseP (RPP30) gene copy numbers using a highly sensitive droplet digital PCR (ddPCR) assay as previously described [18] .
Statistical analysis
Descriptive statistics (median with range or frequency distributions) were used to summarize all demographic information. Median and interquartile range were used to describe the times post dose of the pharmacokinetic blood sampling. Pharmacokinetic data were summarized as geometric mean (GM) and GM ratio [GMR, 90% confidence interval (CI)] of TAF : TDF and compared with a Wilcoxon signed-rank test.
Ethics
The current study was approved by the UNMC Institutional Review Board and all participants provided written informed consent. The study was conducted in accordance with the Declaration of Helsinki.
Results

Study population
Forty-seven participants consented to the study between January 2016 and June 2016, and 30 participants completed both pharmacokinetic sampling visits. The median age of the 30 participants with complete pharmacokinetic data was 39 years (25-58), four (13%) were women, 16 (53%) non-Hispanic white, median CD4 þ cell count was 632 (429-713) cells/ml and all participants had an undetectable (<20 copies/ml) HIV-1 RNA at study entry.
Tenofovir pharmacokinetics
The participants underwent pharmacokinetic sampling after a mean of 82.8 (38.6) weeks of receiving TDF and 5.9 (1.5) weeks of receiving TAF. Plasma TFV and intracellular TFV-DP pharmacokinetic data are summarized in Table 1 and Fig. 1 
Discussion
We found plasma TFV concentrations decreased 90% and intracellular TFV-DP concentrations increased 2.41-fold in participants who were switched from TDF/FTC/ EVG/COBI to TAF/FTC/EVG/COBI as part of routine clinical care. These intraindividual pharmacokinetic data confirm previous observations of 90% lower plasma TFV exposure when comparing TAF to TDF in parallel groups of participants [9, 10] . In addition, this study confirms the higher intracellular TFV-DP concentrations achieved with TAF compared with TDF.
The increase in TFV-DP concentrations in our participants is less than that seen in parallel studies. However, to our knowledge, this is the first study to evaluate plasma and intracellular concentrations within participants, and this difference may simply reflect differences in intraindividual vs. interindividual pharmacokinetic variability. In addition, it must be noted that the dosing duration of TAF differs between the current study and prior reports. The current study investigated TFV plasma and TFV-DP PBMC concentrations after a mean of 5.9 weeks on TAF, ensuring steady state concentrations were reached after switching regimens, as plasma and intracellular TFV and TFV-DP half-lives have been reported as 17 and 87-150 h, respectively. Previous studies have evaluated TFV-DP after as few as 10 days of TAF therapy [19] [20] [21] . In addition, both regimens in this study contained TAF 10 mg once daily combined with the pharmacokinetic booster, COBI; therefore, the results may only be applicable in patients receiving a COBI-boosted ART regimen. Further work is needed to determine the effect of switching patients to or from other ART regimens containing TAF, or other TAF dosing strategies in combination with pharmacokinetic boosters (e.g. TAF 25 mg).
There remain differences in analytical methodology that may account for some of this difference. For example, in our current study, we enumerated PBMC cells via a highly precise ddPCR assay [18] , whereas previous studies of intracellular TFV-DP concentrations have utilized other less precise or less accurate methods of cell enumeration, such as quantitative DNA-based approaches or traditional manual and automated cell counting techniques. Second, we utilized a rapid spin through oil approach when collecting PBMC's for pharmacokinetic analysis. The benefits of the spin through oil approach have been previously described [17] . In addition, our study had the limitation of single, nontimed sample collection which contributes to the pharmacokinetic variability observed in our study. However, intracellular half-lives of TFV-DP of 87 to more than 150 h have been reported in the literature, minimizing the effect of differences in sampling times across the intracellular pharmacokinetic samples.
The pharmacokinetic relationships for plasma TFV pharmacokinetic and pharmacodynamic response as well as drug-related adverse events have been well described [22] [23] [24] [25] . There remains a need to better understand exposure-response relationships with TFV-DP, the intracellular metabolite of TFV. As TFV-DP is the pharmacologically active component of both TDF and TAF formulations, TFV-DP may offer the best option for efficacy-based evaluations. Studies investigating TDF pharmacotherapy as preexposure prophylaxis for the prevention of HIV infection have elegantly described relationships between the number of doses taken, intracellular TFV-DP concentrations, and prevention of HIV infection [26] . Relationships between TFV-DP concentrations and metrics of treatment efficacy (e.g. plasma HIV RNA) for HIV are not as explicitly understood. The data generated via this current study, along with the pharmacokinetic data from previous phase 2 and phase 3 studies of TAF, are reassuring in that higher intracellular concentrations are achieved with lower TAF dosing and lower TFV plasma exposure in patients who switch from TDF to TAF. Furthermore, drug-drug interaction studies to date have identified some differences in p-glycoprotein inducers on TAF vs. TDF, based on plasma drug exposure [1] . These data further inform future drug-drug interaction studies, as intracellular TFV-DP pharmacokinetic data would suggest the threshold for interactions that decrease TAF exposure may be greater with TAF-containing formulations than it is for TDF-containing formulations. Conversely, it remains to be determined whether there is an increased rate of adverse events associated with long-term higher TFV-DP exposure intracellularly, and if so, what the concentration threshold for such adverse events may be. Collectively, these plasma and intracellular pharmacokinetic data of TAF add to the current body of pharmacologic knowledge surrounding the optimal use of TAF in present day antiretroviral therapy.
